Barbara Ruepp
A5025581681- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Occupational and environmental lung diseases
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Cancer Research and Treatments
- Medical Imaging and Pathology Studies
- Neuroendocrine Tumor Research Advances
- Cancer Risks and Factors
- Esophageal Cancer Research and Treatment
- Brain Metastases and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Breast Lesions and Carcinomas
- Poisoning and overdose treatments
International Breast Cancer Study Group
2013-2025
Breast International Group
2017
Dana-Farber Cancer Institute
2017
Frontier Science & Technology Research Foundation
2017
Hospital of Prato
2017
Frontier Science Foundation
2017
Institut Jules Bordet
2017
UPMC Hillman Cancer Center
2014
University of Pittsburgh Medical Center
2014
The Coordinating Center
2014
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
•First randomised, controlled trial evaluating efficacy of an anti-PD1 agent versus chemotherapy in relapsed MPM, with immunotherapy crossover allowed.•Objective response rate was significantly improved for pembrolizumab (22% 6%, P = 0.004).•No improvement independently reviewed PFS over (HR 1.06, 95% CI: 0.73–1.53, 0.76).•No overall survival 1.04, 0.66–1.67, 0.85). BackgroundMalignant pleural mesothelioma (MPM) is aggressive malignancy characterised by limited treatment options and a poor...
JCO
IntroductionMutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported several retrospective trials small series advanced pretreated NSCLC mutations. We report first prospective evaluation afatinib for treatment this molecularly defined entity.MethodsNICHE, a single-arm...
LBA8002 Background: The currently approved frontline TXs for PM are the combination of ipilimumab/nivolumab or platinum plus pemetrexed. addition B to C has been shown improve overall survival in a randomized clinical trial. While combined immunotherapy single agent with is superior alone, there potential synergistic triple C, B, and immunotherapy. Methods: BEAT-meso (NCT03762018) an international open-label, 1:1 phase III trial, stratified by histology stage. objective determine efficacy...
ObjectivesIn 2003 the International Breast Cancer Study Group (IBCSG) initiated TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is role of aromatase inhibitors (AI) treated ovarian function suppression (OFS)? 2-What OFS who remain are tamoxifen?MethodsTEXT patients receive exemestane or tamoxifen OFS. OFS, alone. Treatment was 5 years from randomization.ResultsTEXT...
JCO
In spite of the effectiveness endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as first-line treatment for estrogen receptor (ER)-positive, erb-b2 tyrosine 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral with intravenous (IV)
PURPOSE CD276 (B7-H3) is an immunoregulatory protein that plays important role in the inhibition of T-cell function. overexpressed on a variety human solid cancer cells with limited expression normal tissues, making it appealing target for innovative immunotherapy approaches. Pleural mesothelioma (PM) highly aggressive disease need new treatment options. Our objective was to investigate multicenter PM cohort European Thoracic Oncology Platform Mesoscape project and correlate results...